ATE495442T1 - Zusammensetzungen und verfahren zur erkennung von sirolimus - Google Patents
Zusammensetzungen und verfahren zur erkennung von sirolimusInfo
- Publication number
- ATE495442T1 ATE495442T1 AT06758774T AT06758774T ATE495442T1 AT E495442 T1 ATE495442 T1 AT E495442T1 AT 06758774 T AT06758774 T AT 06758774T AT 06758774 T AT06758774 T AT 06758774T AT E495442 T1 ATE495442 T1 AT E495442T1
- Authority
- AT
- Austria
- Prior art keywords
- sirolimus
- poly
- amino acid
- compounds
- compound
- Prior art date
Links
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title abstract 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title abstract 4
- 229960002930 sirolimus Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- -1 poly(amino acid) Polymers 0.000 abstract 9
- 229920001308 poly(aminoacid) Polymers 0.000 abstract 6
- 230000002163 immunogen Effects 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9493—Immunosupressants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/807—Hapten conjugated with peptide or protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/13—Tracers or tags
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/116,928 US7189582B2 (en) | 2005-04-27 | 2005-04-27 | Compositions and methods for detection of sirolimus |
PCT/US2006/016408 WO2006116727A2 (en) | 2005-04-27 | 2006-04-27 | Compositions and methods for detection of sirolimus |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE495442T1 true ATE495442T1 (de) | 2011-01-15 |
Family
ID=37215578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06758774T ATE495442T1 (de) | 2005-04-27 | 2006-04-27 | Zusammensetzungen und verfahren zur erkennung von sirolimus |
Country Status (6)
Country | Link |
---|---|
US (1) | US7189582B2 (de) |
EP (1) | EP1880215B1 (de) |
AT (1) | ATE495442T1 (de) |
DE (1) | DE602006019575D1 (de) |
ES (1) | ES2358530T3 (de) |
WO (1) | WO2006116727A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007106874A2 (en) * | 2006-03-14 | 2007-09-20 | Autocraft Industries, Inc. | Improved wheelchair |
US7883855B2 (en) | 2006-07-21 | 2011-02-08 | Abbott Laboratories | Immunosuppressant drug extraction reagent for immunoassays |
WO2008082979A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Diagnostic test for the detection of a molecule or drug in whole blood |
US7914999B2 (en) * | 2006-12-29 | 2011-03-29 | Abbott Laboratories | Non-denaturing lysis reagent |
CA2673296C (en) * | 2006-12-29 | 2012-10-16 | Abbott Laboratories | Improved assay for immunosuppressant drugs |
WO2008082984A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Non-denaturing lysis reagent for use with capture-in-solution immunoassay |
US7910378B2 (en) * | 2007-12-14 | 2011-03-22 | Siemens Healthcare Diagnostics Inc. | Methods for detection of hydrophobic drugs |
US20090170218A1 (en) * | 2008-01-02 | 2009-07-02 | Dade Behring Inc. | Methods for detection of cyclosporin a |
US7842475B2 (en) * | 2008-01-08 | 2010-11-30 | Siemens Healthcare Diagnostics Inc. | Stabilization of solid support assay reagents |
US20120237550A1 (en) * | 2011-03-16 | 2012-09-20 | Siemens Healthcare Diagnostics Inc. | Maintaining Antibody-Binding Activity Of Immunosuppressant Drug Conjugates |
US9658218B2 (en) * | 2012-05-07 | 2017-05-23 | Siemens Healthcare Diagnostics Inc. | Determination of total analyte concentration |
WO2016100116A1 (en) * | 2014-12-17 | 2016-06-23 | Siemens Healthcare Diagnostics Inc. | Sandwich assay design for small molecules |
JP6879496B2 (ja) * | 2015-10-29 | 2021-06-02 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドSiemens Healthcare Diagnostics Inc. | 小分子のためのサンドイッチアッセイ |
AU2019262979B2 (en) * | 2018-05-01 | 2023-07-06 | Revolution Medicines, Inc. | C26-linked rapamycin analogs as mTOR inhibitors |
US20190336609A1 (en) | 2018-05-01 | 2019-11-07 | Revolution Medicines, Inc. | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors |
CN110736836B (zh) * | 2018-07-19 | 2023-08-18 | 上海云泽生物科技有限公司 | 一种高灵敏度胶乳增强免疫比浊法测定全血中免疫抑制剂他克莫司的试剂盒 |
JP7319362B2 (ja) | 2018-11-02 | 2023-08-01 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | マクロフィリン結合医薬アッセイに使用するための結合競合剤およびその使用方法 |
CN110174363A (zh) * | 2019-01-09 | 2019-08-27 | 北京九强生物技术股份有限公司 | 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途 |
CN112011516A (zh) * | 2020-09-01 | 2020-12-01 | 江南大学 | 一株西罗莫司单克隆抗体杂交瘤细胞株及其应用 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4153447A (en) * | 1971-04-27 | 1979-05-08 | Schering Aktiengesellschaft | Herbicidal methylphenyl carbamates |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4220722A (en) | 1978-02-10 | 1980-09-02 | Syva Company | Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby |
US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US5169773A (en) * | 1984-10-04 | 1992-12-08 | Sandoz Ltd. | Monoclonal antibodies to cyclosporins |
US4683136A (en) * | 1985-03-06 | 1987-07-28 | Scripps Clinic And Research Foundation | Proteinaceous antigens with conformation-independent and conformation-dependent determinants |
US4661408A (en) | 1986-03-18 | 1987-04-28 | E.I. Du Pont De Nemours And Company | Coated chromium dioxide particles |
US4883751A (en) * | 1986-05-28 | 1989-11-28 | New York University | Specific immunoassay for heparin |
US4769165A (en) | 1987-01-20 | 1988-09-06 | E. I. Du Pont De Nemours And Company | Process for synthesis of ferromagnetic chromium dioxide |
US5089390A (en) | 1987-09-04 | 1992-02-18 | Syntex (U.S.A.) Inc. | 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives |
US5233025A (en) * | 1988-09-02 | 1993-08-03 | Matsushita Electric Industrial Co., Ltd. | Amphetamine protein complex as immunogen for obtaining antibodies specific to methamphetamine |
US4920218A (en) * | 1988-10-12 | 1990-04-24 | Merck & Co., Inc. | Novel hydroxide mediated FK-506 rearrangement process |
CA1316916C (en) | 1988-10-12 | 1993-04-27 | David Askin | Hydroxide mediated fk-506 rearrangement product |
US5698448A (en) * | 1988-12-02 | 1997-12-16 | Soldin; Steven J. | Immunosuppressive drug binding proteins and use |
US5135863A (en) | 1988-12-23 | 1992-08-04 | Syntex (U.S.A.) Inc. | Compositions and methods for determining the presence of amphetamines in a sample suspected of containing amphetamine and/or methamphetamine |
US5508178A (en) | 1989-01-19 | 1996-04-16 | Rose; Samuel | Nucleic acid amplification using single primer |
CA2047717C (en) * | 1989-03-14 | 2000-08-01 | Fred W. Wagner | Monoclonal antibodies for small moieties, methods therefor |
US5101015A (en) | 1989-04-10 | 1992-03-31 | Abbott Laboratories | Reagents for an amphetamine-class fluorescence polarization immunoassay |
US5068323A (en) * | 1989-04-21 | 1991-11-26 | Merck & Co., Inc. | Thermally re-arranged FK-506 derivatives having immunosuppressant activity |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
US5283190A (en) * | 1989-07-31 | 1994-02-01 | Traish Adbulmaged M | Specific monoclonal antibodies against a defined epitope of progesterone receptor and methods for their use |
WO1991010907A1 (en) | 1990-01-22 | 1991-07-25 | Synbiotics Corporation | Pharmacologically active compound screening antibodies and hierarchical cluster analysis |
US5164299A (en) | 1990-03-20 | 1992-11-17 | E. I. Du Pont De Nemours And Company | Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays |
JPH04230389A (ja) | 1990-07-16 | 1992-08-19 | American Home Prod Corp | ラパマイシン誘導体 |
US5023264A (en) * | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5120726A (en) * | 1991-03-08 | 1992-06-09 | American Home Products Corporation | Rapamycin hydrazones |
ES2181734T3 (es) * | 1990-11-20 | 2003-03-01 | Dade Behring Marburg Gmbh | Ensayo inmunologico de ciclosporina. |
US5656434A (en) * | 1990-12-28 | 1997-08-12 | Suntory Limited | Monoclonal antibody against cardiac glycoside and utilization thereof |
US5194447A (en) * | 1992-02-18 | 1993-03-16 | American Home Products Corporation | Sulfonylcarbamates of rapamycin |
NO921449L (no) | 1991-04-17 | 1992-10-19 | American Home Prod | Karbamater av rapamycin |
US5118678A (en) * | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
EP0584217A1 (de) | 1991-05-08 | 1994-03-02 | Vertex Pharmaceuticals Incorporated | RFKBP: eine neue Prolylisomerase und Rapamycin/FK506 bindendes Protein |
US5118677A (en) * | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5340716A (en) | 1991-06-20 | 1994-08-23 | Snytex (U.S.A.) Inc. | Assay method utilizing photoactivated chemiluminescent label |
US5120725A (en) * | 1991-05-29 | 1992-06-09 | American Home Products Corporation | Bicyclic rapamycins |
JPH06502659A (ja) * | 1991-05-31 | 1994-03-24 | ファイザー インク | 免疫抑制剤としてのラパマイシンプロドラッグの使用 |
US5151413A (en) * | 1991-11-06 | 1992-09-29 | American Home Products Corporation | Rapamycin acetals as immunosuppressant and antifungal agents |
US5498597A (en) * | 1992-01-17 | 1996-03-12 | Dana-Farber Cancer Institute, Inc. | FKBP-13, an FK506-binding immunophilin |
WO1993025533A1 (en) * | 1992-06-05 | 1993-12-23 | Abbott Laboratories | Methods and reagents for the determination of immunosuppressive agents |
ZA935110B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935111B (en) * | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5489680A (en) * | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
SG47580A1 (en) | 1992-10-13 | 1998-04-17 | American Home Prod | Carbamates of rapamycin |
US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5302584A (en) * | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5480989A (en) * | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5411967A (en) * | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5260300A (en) * | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5349060A (en) * | 1993-01-07 | 1994-09-20 | American Home Products Corporation | Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents |
GB9307491D0 (en) * | 1993-04-08 | 1993-06-02 | Sandoz Ltd | Organic compounds |
US6455288B1 (en) | 1993-04-08 | 2002-09-24 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases |
US5354845A (en) * | 1993-04-21 | 1994-10-11 | Children's Research Institute | FK-506 and rapamycin specific binding immunophilin |
ES2295093T3 (es) * | 1993-04-23 | 2008-04-16 | Wyeth | Conjugados y anticuerpos de rapamicina. |
AU6711994A (en) | 1993-04-23 | 1994-11-21 | American Home Products Corporation | Rapamycin conjugates and antibodies |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
USRE37421E1 (en) * | 1993-07-16 | 2001-10-23 | Smithkline Beecham Corporation | Rapamycin derivatives |
CA2170873A1 (en) | 1993-09-03 | 1995-03-09 | Dariush Davalian | Fluorescent oxygen channeling immunoassays |
US5373014A (en) * | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5378836A (en) * | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
US5391730A (en) * | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
EP0729471A1 (de) * | 1993-11-19 | 1996-09-04 | Abbott Laboratories | Semisynthetische rapamycin analoge mit immunomodulatorischer wirkung |
US5385909A (en) * | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
CN1046944C (zh) * | 1993-12-17 | 1999-12-01 | 山道士有限公司 | 雷怕霉素类衍生物 |
US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5525610A (en) | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
US5362718A (en) * | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5563145A (en) * | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
AU712193B2 (en) * | 1995-06-09 | 1999-10-28 | Novartis Ag | Rapamycin derivatives |
ATE340586T1 (de) * | 1996-07-30 | 2006-10-15 | Novartis Pharma Gmbh | Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände |
US5922730A (en) * | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
US5952320A (en) * | 1997-01-07 | 1999-09-14 | Abbott Laboratories | Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion |
US6709873B1 (en) * | 1997-04-09 | 2004-03-23 | Isodiagnostika Inc. | Method for production of antibodies to specific sites of rapamycin |
CA2286311A1 (en) * | 1997-04-09 | 1998-10-15 | Isotechnika, Inc. | Method for production of antibodies to specific sites of rapamycin |
US6231982B1 (en) | 1997-12-10 | 2001-05-15 | Dade Behring Inc. | Particle reagents having reduced matrix effects and containing an aldehyde-reactive functional group |
WO2003018573A1 (en) * | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin 29-enols |
US20050208607A1 (en) * | 2004-03-10 | 2005-09-22 | Mark Roberts | Immunoassays for everolimus |
-
2005
- 2005-04-27 US US11/116,928 patent/US7189582B2/en active Active
-
2006
- 2006-04-27 EP EP06758774A patent/EP1880215B1/de active Active
- 2006-04-27 ES ES06758774T patent/ES2358530T3/es active Active
- 2006-04-27 WO PCT/US2006/016408 patent/WO2006116727A2/en active Application Filing
- 2006-04-27 AT AT06758774T patent/ATE495442T1/de not_active IP Right Cessation
- 2006-04-27 DE DE602006019575T patent/DE602006019575D1/de active Active
Also Published As
Publication number | Publication date |
---|---|
US20060246518A1 (en) | 2006-11-02 |
WO2006116727A2 (en) | 2006-11-02 |
EP1880215B1 (de) | 2011-01-12 |
WO2006116727A3 (en) | 2007-03-08 |
EP1880215A4 (de) | 2008-05-14 |
EP1880215A2 (de) | 2008-01-23 |
ES2358530T3 (es) | 2011-05-11 |
DE602006019575D1 (de) | 2011-02-24 |
US7189582B2 (en) | 2007-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE495442T1 (de) | Zusammensetzungen und verfahren zur erkennung von sirolimus | |
WO2004072235A3 (en) | Cotton event mon 88913 and compositions and methods for detection thereof | |
EP2333116A3 (de) | Marker für Nierentransplantatabstoßung und Nierenschäden | |
FR2848850B1 (fr) | Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates. | |
WO2004053062A3 (en) | Bentgrass event asr-368 and compositions and methods for detection thereof | |
WO2005059103A3 (en) | Corn plant mon88017 and compositions and methods for detection thereof | |
WO2007035864A3 (en) | Electrophoresis standards, methods and kits | |
AR057914A1 (es) | Compuestos organicos de azufre y su uso | |
EP2248869A3 (de) | Verbindungen für organische elektronische Vorrichtungen | |
WO2012022982A3 (en) | Improved antibodies of the class igg4 | |
WO2008020823A3 (en) | Cooperative reporter systems, components, and methods for analyte detection | |
DE602005027859D1 (de) | An ein substrat gebundene dendrimere | |
BRPI0607323A2 (pt) | composições e uso de polipeptìdeos e kits para a detecção de anticorpo que se liga especificamente a um polipeptìdeo | |
DE602004011105D1 (de) | Verfahren, peptide und biosensoren mit eignung zum nachweis eines breiten spektrums von bakterien | |
WO2005016115A3 (en) | Biosensors utilizing dendrimer-immobilized ligands and their use thereof | |
CY1116208T1 (el) | Υδατο-διαλυτη ενωση βενζοαζεπινης και η φαρμακευτικη συνθεση αυτης | |
ATE490986T1 (de) | Polymer, vernetztes polymer, zusammensetzung für ein feststoffpolymer-elektrolyt, feststoffpolymer-elektrolyt und klebstoffzusammensetzung | |
WO2009024805A8 (en) | An enzyme detection device | |
WO2009083225A3 (en) | Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis | |
EA201000814A1 (ru) | 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств | |
WO2008081938A1 (ja) | 耐熱性ビオチン結合性タンパク質の利用法、および当該タンパク質が結合した固体担体 | |
ATE316531T1 (de) | Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1 | |
EA200300478A1 (ru) | Полизамещенные имидазопиридины в качестве ингибиторов желудочной секреции | |
TWI318688B (de) | ||
ATE420918T1 (de) | Sauerstoffbarriereformulierungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |